Enhancing the anticancer effects of 5-fluorouracil: Current challenges and future perspectives

Biomedical Journal

Volumn 38, Issue 2, 2015, Pages 111-116

  Ghiringhelli, François ^a,b,c   Apetoh, Lionel ^a,b,c  

^a boulevard Jeanne d'Arc   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

5 fluorouracil; Anticancer immunity; Immunomodulation; Immunosuppression; Inflammasome; Myeloid derived suppressor cell

Indexed keywords

ADENOVIRUS VACCINE; CRYOPYRIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAS LIGAND; FLT3 LIGAND; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; OXALIPLATIN; PACLITAXEL; PROTEIN BAX; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; TOLL LIKE RECEPTOR 4; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; DRUG SENSITIZATION; EFFECTOR CELL; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LOW DRUG DOSE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; IMMUNOLOGY; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; T-LYMPHOCYTES;

EID: 84928542659     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.130923     Document Type: Article

References (39)

1. Rutman RJ, Cantarow A, Paschkis KE. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res 1954;14:119-23.
2. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663-6.
3. Wohlhueter RM, McIvor RS, Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 1980;104:309-19.
4. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6.
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
6. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61.
7. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
8. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009;15:1170-8.
9. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: Moving towards more personalized medicine. Trends Mol Med 2008;14:141-51.
10. Lake RA, Robinson BW. Immunotherapy and chemotherapy- a practical partnership. Nat Rev Cancer 2005;5:397-405.
11. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the NLRP3 inflammasome and promotes tumor growth. Nat Med 2013;19:57-64.
12. Ghiringhelli F, Apetoh L. The interplay between the immune system and chemotherapy: Emerging methods for optimizing therapy. Expert Rev Clin Immunol 2014;10:19-30.
13. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8:151-60.
14. Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 2003;14:833-43.
15. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001;50:445-5.
16. Backus HH, Dukers DF, van Groeningen CJ, Vos W, Bloemena E, Wouters D, et al. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol 2001;12:209-16.
17. Eisenthal A, Eytan K, Brazowski E, Katz BZ, Shirazi I, Skornick Y. Effects of 5-fluorouracil on human mitogen-activated peripheral blood lymphocytes from healthy individuals. Anticancer Res 2008;28:3785-91.
18. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
19. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
20. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
21. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21.
22. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70:3052-61.
23. Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol 2013;17:1141-7.
24. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72.
25. Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 2012;32:5363-9.
26. Gol b J, Zagozdzon R, Kaminski R, Kozar K, Gryska K, Izycki D, et al. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 2001;15:613-20.
27. Cao S, Troutt AB, Rustum YM. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res 1998;58:1695-9.
28. Hou S, Kou G, Fan X, Wang H, Qian W, Zhang D, et al. Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU. Cancer Immunol Immunother 2007;56:1605-13.
29. Khallouf H, Marten A, Serba S, Teichgraber V, Buchler MW, Jager D, et al. 5-Fluorouracil and interferon-alpha immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother 2012;35:245-53.
30. Aketa H, Tatsumi T, Kohga K, Tsunematsu H, Aono S, Shimizu S, et al. The combination therapy of alpha-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice. Int J Cancer 2013;133:1126-34.
31. Nagasaki E, Takahara A, Koido S, Sagawa Y, Aiba K, Tajiri H, et al. Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway. J Immunother 2010;33:467-74.
32. Tanaka F, Yamaguchi H, Ohta M, Mashino K, Sonoda H, Sadanaga N, et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer 2002;101:265-9.
33. Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, et al. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 2005;97:1437-45.
34. Geary SM, Lemke CD, Lubaroff DM, Salem AK. The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS One 2013;8:e67904.
35. Berger H, Vegran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, et al. SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth. Cancer Res 2013;73:3578-90.
36. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-7.
37. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009;1:CD005121.
38. Ghiringhelli F, Bruchard M, Apetoh L. Immune effects of 5-fluorouracil: Ambivalence matters. Oncoimmunology 2013;2:e23139.
39. Zhang P, Su DM, Liang M, Fu J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 2008;45:1470-6.